Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3841136 + Tirzepatide in Obesity
NCT06345066Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2024
- Primary completion
- Sep 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing LY3841136 + Tirzepatide with Placebo + Tirzepatide (2 arms). Primary endpoint: Treatment Emergent Adverse Events and Serious Adverse Events at 42 weeks. Started Apr 2024; status: completed.
02
Drugs
eloralintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06345066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06345066.